Date: 2014-09-23
Type of information: IPO
Company: Foamix Pharmaceuticals (Israel - USA - NJ)
Investors:
Amount: $35.7 million
Funding type: IPO
Planned used:
Others: * On September 23, 2014, Foamix Pharmaceuticals, a clinical stage specialty pharmaceutical company focused on developing and commercializing its proprietary topical foams to address unmet needs in dermatology, announced the closing of its initial public offering. A total of 6.7 million ordinary shares were sold at a price to the public of $6.00 per share. In addition, Foamix has granted the underwriters a 30 day option to purchase up to 1,005,000 additional ordinary shares. The shares are trading on the NASDAQ Global Market under the ticker symbol \"FOMX.\" The net proceeds from the sale of shares, after deducting underwriting discounts, commissions and other estimated offering expenses, will be approximately $35.7 million. * On September 18, 2014, Foamix Pharmaceuticals announced the pricing of its initial public offering of 6.7 million ordinary shares at a price to the public of $6.00 per share. All of the ordinary shares are being offered by Foamix Pharmaceuticals. In addition, Foamix has granted the underwriters a 30-day option to purchase up to 1,005,000 additional ordinary shares. The shares are expected to begin trading on the NASDAQ Global Market on Thursday, September 18, 2014, under the ticker symbol \"FOMX.\" The offering is expected to close on Tuesday, September 23, 2014, subject to customary closing conditions. Barclays Capital Inc. and Cowen and Company, LLC are acting as joint book-running managers for the offering. Oppenheimer & Co. Inc. and Maxim Group LLC are acting as co-managers. The offering of these securities will be made only by means of a written prospectus.
Therapeutic area:
